Clinical Outcomes at 3 and 6 Months of Fedratinib Therapy Following Prior Ruxolitinib Failure for Myerlofibrosis: Real-World Assessment of Spleen, Symptoms, and Hematologic Response
Patients with myelofibrosis treated with fedratinib were treated primarily for progressive disease after ruxolitinib failure in the real-world setting. There were statistically significant reductions in spleen size and symptom burden after three and six months of treatment.
Professor of Medicine (Hematology and Medical Oncology)
Director, Center of Excellence for Blood Cancers and Myeloid Disorders
Director, Adult Leukemia Program
Mount Sinai Tisch Cancer Center